Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.46 |
| ▸ | WNT3A | P56704 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395494 | 0.86 | MAPT (0.56) | MAPTKMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL3563696 | 0.85 | CES2 (0.55) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL28436031 | 0.82 | PTPN1 (0.55) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL21758650 | 0.81 | CTNNB1 (0.51) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL7001279 | 0.78 | CES2 (0.50) | CES2CES1MAPTKMT2AMEN1 | |
| SCHEMBL11493775 | 0.78 | MAPT (0.50) | MAPTKMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL7614948 | 0.78 | ALDH1A1 (0.56) | MAPTKMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL11344457 | 0.78 | CES2 (0.55) | CES2CES1MAPTKMT2AMEN1 | |
| SCHEMBL30029385 | 0.78 | CES2 (0.55) | CES2CES1MAPTKMT2AMEN1 | |
| SCHEMBL5931410 | 0.78 | CES2 (0.55) | CES2CES1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110526867-A | A method of efficiently preparing blonanserin intermediate | HUNAN XIANGZHONG PHARMACEUTICAL CO LTD | 2019-12-03 | — | — | CN | claimed |
| CN-107056653-B | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2019-07-09 | — | — | CN | claimed |
| CN-107056653-A | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | claimed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| WO-2025064210-A1 | INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) | BLOOD CELL TECHNOLOGIES, LLC (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119192171-A | Small molecule compounds and their use in vitro expansion of hematopoietic stem cells and/or progenitor cells | 上海交通大学医学院 | 2024-12-27 | — | — | CN | disclosed |
| CN-117624188-A | Cyclopentathiofuran carboxamide derivatives as platelet-activating factor receptor antagonists | 勃林格殷格翰国际有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-4259256-A | ANTIINFLAMMATORY | AMERICAN CYANAMID COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4197312-A | USE TO INHIBIT ARTHRITIS AND PROGRESSIVE JOINT DETERIORATION AND AS ANTIINFLAMMATORIES | AMERICAN CYANAMID COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
| US-4197312-A | USE TO INHIBIT ARTHRITIS AND PROGRESSIVE JOINT DETERIORATION AND AS ANTIINFLAMMATORIES | AMERICAN CYANAMID COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
| US-4181677-A | ANTIINFLAMMATORY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | disclosed |
| US-4083993-A | ARTHRITIS | AMERICAN CYANAMID CO. (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | PTPN1 1079/4885ERCC5 2183/4885FEN1 2742/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | PTPN1 1583/4885ERCC5 4743/4885FEN1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.